CTCs Could Shorten Drug Trials.
In a phase III study, circulating tumor cells and blood levels of the enzyme lactate dehydrogenase predicted survival in patients with metastatic prostate cancer. Use of these biomarkers as surrogate predictors of survival could speed clinical trials of experimental therapies for prostate cancer.